KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Retained Earnings (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Retained Earnings for 7 consecutive years, with $2.4 billion as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 17.2% to $2.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 billion through Dec 2025, down 17.2% year-over-year, with the annual reading at $2.4 billion for FY2025, 17.2% down from the prior year.
  • Retained Earnings hit $2.4 billion in Q4 2025 for Royalty Pharma, up from $2.3 billion in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $2.8 billion in Q4 2024 to a low of $12.3 million in Q1 2022.
  • Historically, Retained Earnings has averaged $1.8 billion across 5 years, with a median of $2.3 billion in 2021.
  • Biggest five-year swings in Retained Earnings: plummeted 99.43% in 2022 and later surged 17916.99% in 2023.
  • Year by year, Retained Earnings stood at $16.5 million in 2021, then surged by 11813.7% to $2.0 billion in 2022, then grew by 28.14% to $2.5 billion in 2023, then increased by 13.03% to $2.8 billion in 2024, then dropped by 17.2% to $2.4 billion in 2025.
  • Business Quant data shows Retained Earnings for RPRX at $2.4 billion in Q4 2025, $2.3 billion in Q3 2025, and $2.2 billion in Q2 2025.